Exclusive Summary

• Ticagrelor's originator patents have expired in all major markets; with both FDA and EMA GMP certifications plus registrations across the US and 27 EU countries, the Chinese supplier can immediately enter high-value distribution channels without additional regulatory barriers.
• The global ACS patient base exceeds 20 million new cases annually, and the combination of 60mg (long-term prevention) and 90mg (acute phase) strengths covers the full treatment continuum, ensuring stable and recurring demand.
• Ticagrelor holds a Class I, Level A recommendation in ESC and ACC/AHA guidelines as the preferred P2Y12 inhibitor for ACS, and is listed on the WHO Essential Medicines List, making procurement and reimbursement justification straightforward for buyers.
• Generic pricing is typically 10–30% of the originator (Brilinta/AstraZeneca), offering substantial margin for distributors and strong competitiveness in price-sensitive markets such as Central & Eastern Europe and Latin America.
• Dual FDA + EMA certification combined with 27-country EU registration positions the supplier as a one-stop, fully compliant partner for multinational distributors seeking to streamline their supply chain across multiple regions.